ENPP7P12: A Potential Drug Target and Biomarker (G106480230)

Target Name: ENPP7P12

NCBI ID: G106480230

ENPP7P12

Other Name(s): Ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 12 | ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 12

ENPP7P12: A Potential Drug Target and Biomarker

ENPP7P12, also known as ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 12, is a gene that encodes a protein involved in the regulation of nucleotide metabolism. The ENPP7P12 gene is located on chromosome 11q22 and has been implicated in various cellular processes, including DNA replication, transcription, and gene expression.

Recent studies have identified ENPP7P12 as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ENPP7P12 has also been associated with several adverse cardiovascular events, including myocardial infarction, stroke, and sudden infant death syndrome (SIDS).

The ENPP7P12 gene has been shown to play a crucial role in the development and progression of various diseases. For example, studies have shown that ENPP7P12 is highly expressed in cancer tissues and is associated with poor prognosis in cancer patients. Additionally, ENPP7P12 has been shown to be involved in the regulation of cellular processes that are critical for brain development and function, including cell survival, proliferation, and migration.

Furthermore, ENPP7P12 has been linked to several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurogenic infarctions. ENPP7P12 has been shown to be involved in the regulation of the production of neurotransmitters, which are critical for the functioning of nerve cells.

In addition to its role in neurodegenerative diseases, ENPP7P12 has also been associated with several autoimmune disorders, including type 1 diabetes, rheumatoid arthritis, and lupus. These conditions are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. ENPP7P12 has been shown to be involved in the regulation of immune cell function and the production of autoantibodies.

ENPP7P12 has also been linked to several adverse cardiovascular events, including myocardial infarction, stroke, and sudden infant death syndrome (SIDS). These events are characterized by the blockage or rupture of blood vessels, leading to tissue damage and death. ENPP7P12 has been shown to be involved in the regulation of cell signaling pathways that are critical for cardiovascular function, including the regulation of blood pressure and cholesterol levels.

In conclusion, ENPP7P12 is a gene that has been implicated in various cellular processes that are critical for human health and wellbeing. The studies have shown that ENPP7P12 is a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, autoimmune disorders, and cardiovascular disease. Further research is needed to fully understand the role of ENPP7P12 in these conditions and to develop effective treatments.

Protein Name: Ectonucleotide Pyrophosphatase/phosphodiesterase 7 Pseudogene 12

The "ENPP7P12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENPP7P12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets